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OBJECTIVE—During diabetes, retinal microglial cells are acti-
vated to release inﬂammatory cytokines that initiate neuronal
loss and blood–retinal barrier breakdown seen in diabetic reti-
nopathy (DR). The mechanism by which diabetes activates
microglia to release those inﬂammatory mediators is unclear
and was therefore elucidated.
RESEARCH DESIGN AND METHODS—Microglia activation
was characterized in streptozocin-injected rats and in isolated
microglial cells using immunoﬂuorescence, enzyme-linked immu-
nosorbent assay, RT-PCR, and Western blot analyses.
RESULTS—In 8-week diabetic retina, phospho-extracellular
signal–related kinase (ERK) and P38 mitogen-activated protein
kinases were localized in microglia, but not in Mueller cells or
astrocytes. At the same time, Amadori-glycated albumin (AGA)-
like epitopes were featured in the regions of microglia distribu-
tion, implicating a pathogenic effect on microglial activation. To
test this, diabetic rats were treated intravitreally with A717, a
speciﬁc AGA-neutralizing antibody, or murine IgG. Relative to
nondiabetic rats, diabetic rats (IgG-treated) manifested 3.9- and
7.9-fold increases in Iba-1 and tumor necrosis factor (TNF)-a
mRNAs, respectively. Treatment of diabetic rats with A717 sig-
niﬁcantly attenuated overexpression of these mRNAs. Intravitreal
injection of AGA per se in normal rats resulted in increases of
Iba-1 expression and TNF-a release. Guided by these results,
a cultured retinal microglia model was developed to study micro-
glial response after AGA treatment and the mechanistic basis
behind this response. The results showed that formation of re-
active oxygen species and subsequent activation of ERK and P38,
but not Jun NH2-terminal kinase, are molecular events underpin-
ning retinal microglial TNF-a release during AGA treatment.
CONCLUSIONS—These results provide new insights in un-
derstanding the pathogenesis of early DR, showing that the
accumulated AGA within the diabetic retina elicits the microglial
activation and secretion of TNF-a. Thus, intervention trials with
agents that neutralize AGA effects may emerge as a new thera-
peutic approach to modulate early pathologic pathways long be-
fore the occurrence of vision loss among patients with diabetes.
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D
uring the past decade, it has become clear that
inﬂammation is a key feature in diabetes that
leads to long-term complications in speciﬁc
organs, in particular the eye and kidney (1). In
the eye, the major complication is diabetic retinopathy
(DR), which is the leading cause of blindness in the western
world and affects approximately three fourths of diabetic
patients within 15 years after onset of the disease (2). The
recommended treatment for these patients has been laser
photocoagulation, which is an invasive procedure with con-
siderable limitations and adverse effects. Therefore, there
is a great need for the development of new noninvasive
therapies to treat those affected by DR. These therapies
can be discovered by unraveling the pathophysiology
of DR.
As a consequence of diabetes, retinal microglia, a sub-
type of glial-immune sentinel cells prestationed in the tis-
sue, become reactive, leading to the release of soluble
cytotoxins that contribute to neuronal and vascular cell
death and ultimately the progression of DR (3). However,
the underlying mechanism of microglial activation during
diabetes is still incompletely understood.
In recent years, human and animal studies have eluci-
dated that many effects of hyperglycemia are mediated by
glycated proteins (4). Amadori-glycated albumin (AGA) is
the prominent form of circulating glycated proteins in vivo,
and its concentration is signiﬁcantly increased after di-
abetes, reaching its maximum in 5–7 weeks (5). AGA arises
from the nonenzymatic condensation reaction between a
reducing sugar and susceptible amino groups. This mod-
iﬁcation confers properties to AGA that are not possessed
by the native, nonglycated albumin, such as the promotion
of the inﬂammatory response and the activation of differ-
ent mitogen-activated protein kinase (MAPK) cascades in
several cell types (6–9). These MAPKs, including extracel-
lular signal–related kinase (ERK), Jun NH2-terminal kinases
(JNKs), and P38, can be independently or simultaneously
activated depending on the target cells (8–10).
On the basis of these properties of AGA, a growing body
of evidence now supports the causal role of AGA in the
development of many complications associated with di-
abetes (11–13). In relation to DR, elevated AGA has been
documented in the retinal capillaries of diabetic patients
with retinopathy (14) and in the retina of diabetic rats (15).
Treatment of diabetic db/db mice with A717 antibody, which
speciﬁcally recognizes AGA, ameliorated retinal basement
membrane thickening (16). Furthermore, treatment of di-
abetic rats with 2-(3-chlorophenylamino)-phenylacetic acid,
which inhibits the nonenzymatic glycation of albumin, miti-
gated vitreous changes in angiogenic cytokines associated
with the development of DR (17). Therefore, AGA is be-
lieved to possess biologic characteristics that are linked to
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ORIGINAL ARTICLEthe DR pathogenesis and might be involved in the activation
of retinal microglia. In the present work, we aimed to study
the ability of AGA to induce retinal microglial activation and
their secretion of inﬂammatory cytokines both in vivo and
in vitro.
RESEARCH DESIGN AND METHODS
All procedures with animals were performed in accordance with the Asso-
ciation for Research in Vision and Ophthalmology Statement for the Use of
Animals in Ophthalmic and Vision Research and Medical College of Georgia
guidelines. Diabetes was induced in male SD rats by intravenous injection of
streptozocin (STZ) (60 mg/kg) and conﬁrmed by urine-glucose levels .350
mg/dL. Eyes were used for immunoﬂuorescence or Western examination
at 8 weeks of diabetes. For intravitreal injections, the procedure was essen-
tially the same as previously described (18). The A717 intravitreal injection
scheme was chosen on the basis of certain assumptions regarding the esti-
mated amount of AGA to be neutralized. We estimated rat vitreous volume at
50 mL (19), with AGA concentration of 1.9 mg/mL (17). This would corre-
spond with an approximate total vitreous AGA of 0.09 mg. On a stoichio-
metric basis, it would require ;0.2 mg antibody (mol wt ;150 kD) to
neutralize ;0.09 mgo fA G A( m o lw t;66.5 kD). First, A717 injections were
given at 10 days, and a booster dose was given at 7 weeks of diabetes. These
two time points were selected presumably because the former represents
the earliest occurrence of AGA, whereas the latter marks its maximum
accumulation (5).
Microglia culture. Microglia were isolated from retinas of newborn SD rats
according to a previous procedure (20). Cell viability after various drug
treatments was determined by counting the number of trypan blue-excluding
cells using a hemocytometer.
AGA preparation. AGA was purchased from Sigma-Aldrich Co. (St. Louis,
MO), puriﬁed by afﬁnity chromatography on phenylboronate resin, concen-
trated, and desalted into PBS. This preparation contains 2.2-mol hexose-lysine/
mol-albumin, but ﬂuorescent advanced glycation end products (AGEs) were
not detectable and the major AGE N-(carboxymethyl) lysine was present in
only minute amounts (21). The concentration of AGA (500 mg/mL) chosen in
our study is close to what has been used previously to study other glycated
albumin-mediated responses (22) and represents those found in clinical
specimens (23). The speciﬁcity of AGA activity was determined by neutrali-
zation with its antibody, A717. Brieﬂy, AGA or BSA was balanced with PBS at
pH = 7.4, kept overnight at 4°C on a rocker with A717 antibody or IgG, served
as a control, and followed by the addition of A/G agarose beads. The beads
were then removed by centrifugation, and the supernatant was collected and
used for microglia treatment. The endotoxin level was checked by an endo-
toxin testing kit (Limulus amebocyte assay, E-Toxate, Sigma-Aldrich Co.).
Alternatively, AGA was purchased from Exocell Inc. (Philadelphia, PA). This
alternative product contains 1-mol hexose-lysine/mol-albumin and was puri-
ﬁed by boronate-afﬁnity column and Detoxi-Gel Endotoxin Removal Gel.
Viability of cells after AGA-treatment was checked by transferase-mediated
dUTP nick-end labeling assay (Trevigen Inc., Gaithersburg, MD) following the
manufacturer’s instructions.
Immunoﬂuorescence. Dual-labeled immunoﬂuorescence analysis was per-
formed using frozen retinal sections. Brieﬂy, sections were ﬁxed in 4% para-
formaldehyde, blocked with 10% normal goat serum, and then incubated with
primary antibodies (Table 1) overnight. Thereafter, sections were brieﬂy
washed with PBS and incubated with appropriate secondary antibodies (Table
1). Slides were examined by confocal microscopy (LSM 510, Carl Zeiss AG,
Oberkochen, Germany). Speciﬁcity of the reaction was conﬁrmed by omitting
the primary antibody. Images were collected from ﬁve sections per rat of at
least four to six rats per group.
RNA interference. Microglial cells were transfected with ERK or control
small interfering (si)RNAs (Ambion, Austin, TX) using HiPerFect (Qiagen,
Venlo, the Netherlands) per the manufacturer’s instructions.
Quantitative real-time PCR. Total RNA was isolated from rat retina using
a Promega kit (Promega Corp., Madison, WI). Subsequently, cDNAs were
generated from 1 mg of total RNA, using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA), and subjected to a 40-
cycle PCR ampliﬁcation. The ready-made primer and probe sets were ordered
from Applied Biosystems (Catalog: Iba-1: Rn01525935_m1; TNF-a: Rn99999017_m1;
18S: Hs03003631_g1). Three replicates were run for each gene for each sample
in a 96-well plate. 18S was used as the endogenous reference gene.
Western blot analysis. Cell or retinal lysates were subjected to Western blot
analysis using antibodies speciﬁed in Table 1 according to a previous pro-
cedure (20).
ELISA assay. Tumor necrosis factor (TNF)-a levels in the rat vitreous or
supernatants of culture media were estimated with ELISA kit (R&D Systems
Inc., Minneapolis, MN) per the manufacturer’s instructions (20).
DCF assay for reactive oxygen species formation. DCF, the oxidation
product of the reagent 2`,7`-dichloroﬂuorescin diacetate, was used as a marker
of cellular oxidation according to a previous procedure (20).
Data analysis. The results were expressed as mean 6 SD. Differences among
experimental groups were evaluated by ANOVA, and the signiﬁcance of dif-
ferences between groups was assessed by the post hoc test (Fisher pro-
tected least signiﬁcant difference) when indicated. Signiﬁcance was deﬁned
as P , 0.05.
TABLE 1
Primary antibodies used for different experiments in this study
Antibody Catalog no. Vendor Host
Working
dilution
IF WB
Anti-Iba1 019–19741 Wako Rabbit 1:200 —
Anti-OX-42 201801 BioLegend (San Diego, CA) Mouse 1:200 —
Antiphospho-ERK 9106 Cell Signaling Technology Inc. (Danvers, MA) Mouse 1:400 1:2,000
Antiphospho-P38 4631 Cell Signaling Technology Inc. Rabbit 1:100 1:1,000
Anti-GFAP AB5541 Millipore (Billerica, MA) Chicken 1:500 —
Anti-AGA A717 Exocell Inc. (Philadelphia, PA) Mouse 1:50 1:500
Anti-albumin PA1–10298 Thermo Fisher Scientiﬁc (Waltham, MA) Rabbit — 1:2,000
Antiactin A2066 Sigma-Aldrich Co. (St. Louis, MO) Rabbit — 1:2,000
Anti-ERK 9102 Cell Signaling Technology Rabbit — 1:1,000
Anti-P38 9212 Cell Signaling Technology Rabbit — 1:1,000
Antiphospho-JNK 9255 Cell Signaling Technology Mouse — 1:2,000
Anti-JNK 9252 Cell Signaling Technology Rabbit — 1:1,000
Anti-rabbit (Texas red or Oregon green) A21072 Invitrogen (Carlsbad, CA) Goat 1:500 —
737677 Chicken
Anti-mouse (Texas red or Oregon green) 737674 Invitrogen Chicken 1:500 —
A11017 Goat
Antichicken (Cya5) 92590 Millipore Donkey 1:500 —
Anti-rabbit HRP 7074 Cell Signaling Technology Goat — 1:10,000
Anti-mouse HRP 7076 Cell Signaling Technology Goat — 1:10,000
HRP, horseradish peroxidase; IF, immunoﬂuorescence; WB, Western blot.
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ERK and P38 MAPKs are selectively activated in the
retinal microglia during diabetes. Recent evidence has
shown that MAPK cascade is one of the attractive targets
for intervention in the inﬂammatory-associated diseases,
such as diabetes. Therefore, the role of retinal microglia
and macroglia during diabetes was investigated by de-
termining MAPK signaling in frozen eye sections. As
shown in Fig. 1A and B, in the 8-week diabetic retina,
numerous Iba-1- or OX-42-positive cells (activated micro-
glia) appeared hypertrophic or amoeboid and were ob-
served in the outer plexiform layer or ganglion cell layer,
or frequently clustered around the perivascular region
(Supplementary Fig. 1). In contrast, in the nondiabetic
retina, these cells had oval cell bodies with ramiﬁed pro-
cesses (Supplementary Fig. 2). Double immunoﬂuores-
cence showed that pERK- and pP38-labeled cells were
colocalized with Iba-1 or OX-42 antigen, but not with glial
ﬁbrillary acidic protein (GFAP). These results revealed
that diabetes leads to characteristic glial cell changes
within the retina in which activation of ERK and P38 occur
in the activated microglia, but not in astrocytes or Mueller
cells.
AGA is a proinﬂammatory trigger in diabetes-induced
retinal microglial activation and inﬂammation. The
induction of microglial reactivity is associated with a local
proinﬂammatory environment (3,24) that could be trig-
gered by various conditions operating in the course of di-
abetes. Given the fact that AGA provokes proinﬂammatory
responses in many types of cells, including immune cells
(7,9,25), we hypothesized that this glycated protein may
also be implicated in diabetes-induced microglial activa-
tion and retinal inﬂammation. To test this, we ﬁrst sought
to determine whether this glycated protein is accumulated
in the diabetic retina and whether this accumulation
occurs in the region of microglia distribution. The results
FIG. 1. Activation of ERK and P38 in diabetes occurs in the retinal microglia. Immunolabeling of phospho-ERK (green) (A) or phospho-P38 (green)
(B) with Iba-1 (red) or OX-42 (red), markers of activated microglia, or with GFAP (red), a marker of astrocytes or activated Mueller cells, was
made in the retinas of diabetic (8 weeks after STZ induction) and normal rats. Yellow displayed from merged red and green. Scale bar, 20 mm. GCL,
ganglion cell layer. H&E, hematoxylin–eosin stain; OPL, outer plexiform layer. (A high-quality digital representation of this ﬁgure is available in
the online issue.)
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mately 4.5- and fourfold in the retina of 8-week diabetic
rats compared with nondiabetic retinas (Fig. 2A and B).
Moreover, AGA-like epitopes were featured within the ret-
inal tissue of 8-week diabetic rats (Fig. 2C) and at 10 days
after the detection of hyperglycemia (data not shown).
These epitopes were found to be colocalized with the
microglial marker (Fig. 2C), implicating a pathogenic ef-
fect on microglial function.
Second, to determine whether AGA is involved in the
pathogenesis of microglial activation and inﬂammation
during diabetes, we used two complementary approaches. In
our ﬁrst approach, the putative biological effect of AGA per
se in retinal inﬂammation was investigated using an experi-
mental model in which normal rats were injected intra-
vitreally with AGA or nonglycated albumin. As shown in
Fig. 2D and E, AGA injection induced a signiﬁcant ﬁve- and
3.3-fold increase in retinal Iba1 mRNA expression and TNF-a
release, respectively, compared with controls injected with
nonglycated albumin.
The second approach was to assess whether neutralizing
AGA biological activity in the diabetic retinas with A717
FIG. 2. AGA as a proinﬂammatory trigger in diabetes-induced retinal microglial activation and inﬂammation. A and B: AGA and albumin expression
in retina of nondiabetic rats (normal) and 8-week diabetic rats, analyzed by Western blot. Ratio of the intensities of AGA or albumin relative to the
actin for the patients with diabetes was compared with normal, which was arbitrarily set at 1.0. Data shown for the comparison of normal and
diabetic rats are the mean 6 SD and representative of four to six animals per group. C: Immunolabeling of AGA (green) with Iba-1 (red) in the
normal and 8-week diabetic rat retinas. D: Activation of retinal microglia by injected AGA in normal rats. Nondiabetic rats were injected intra-
vitreally with AGA (500 mg/mL) or equal amounts of nonglycated albumin. Retinal Iba-1 mRNA was determined by real-time PCR 24 h later. Data
shown are the mean 6 SD (n =4 –6). E: Proinﬂammatory effect of injected AGA in normal rat retina. Nondiabetic rats were injected intravitreally
with AGA (500 mg/mL) or equal amounts of BSA. Vitreal TNF-a was determined by ELISA 24 h later. Data shown are the mean 6 SD (n =4 –6).
F and G: Attenuation of increased Iba1 and TNF-a gene expression in diabetic rats treated with A717 or IgG. Total RNA was extracted from snap-
frozen retinas, and Iba1 and TNF-a mRNAs were then determined by real-time PCR and normalized to normal nondiabetic control. Data shown are
the mean 6 SD (n =4 –6). H: Cyclic threshold values of 18S in the retina of diabetic rats treated with A717 or IgG. Data shown are the mean 6 SD
(n =4 –6). Ct, cyclic threshold; GCL, ganglion cell layer; OPL, outer plexiform layer. (A high-quality color representation of this ﬁgure is available
in the online issue.)
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tion and TNF-a r e l e a s e .A ss h o w ni nF i g .2 F and G, treat-
ment with A717 signiﬁcantly decreased the elevated retinal
Iba1 and TNF-a gene expression observed in the IgG-treated
diabetic rats by ;60 and 65%, respectively. Of note, the ex-
pression level of 18S was approximately the same among
diabetic groups (Fig. 2H), indicating that the effect of A717 on
gene expression is not due to a generalized nonspeciﬁc sup-
pression of retinal gene expression. Taken together, these
results demonstrate that the formation of AGA within the
diabetic milieu is one of the major contributing factors to
microglial activation and therefore retinal inﬂammation.
FIG. 3. AGA induces TNF-a release by retinal microglial cells in vitro. A: Characterization of retinal microglial cells by immunocytochemistry and
ﬂow cytometry. The panel contains a bright ﬁeld view and immunodetection of Iba1 (red), GFAP (green), and ﬂow cytometric analysis to de-
termine cell purity. For ﬂow cytometry analysis, cells with ﬂuorescent intensity in M1 region were determined as positive for Iba1 and their
percentage in the total population is shown. Normal rabbit IgG was used as control. B: Time-dependent release of TNF-a in AGA-treated retinal
microglial cells. Cells were treated with AGA (500 mg/mL) or an equal level of nonglycated albumin for the indicated time. TNF-a levels in the
culture media were measured by ELISA. Data shown are the mean 6 SD of three experiments. C–G: TNF-a production in microglial cells after 4-h
incubation with (C) puriﬁed lipopolysaccharide (0.1–1,000 ng/mL); (D) media containing 1 mg/mL LPS or 500 mg/mL AGA in the presence or
absence of 1 mg/mL polymyxin B; (E) 500 mg/mL of BSA, unpuriﬁed, puriﬁed AGA; (F) 500 mg/mL of BSA, AGA with 2.2 mol hexose/albumin, or
1 mol hexose/albumin; (G) 500 mg/mL of BSA or AGA neutralized by A717 or IgG, which served as isotypic control. Data shown are the mean 6 SD
of three experiments. PBM, polymyxin B. (A high-quality color representation of this ﬁgure is available in the online issue.)
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induced activation of ERK in retinal microglial cells. Cells were treated with 500 mg/mL AGA for 1–8 h. Phospho (p)ERK and its total protein in cell
lysate were determined by Western analysis. Ratios of the intensities of phospho-proteins relative to total proteins for each time point were
compared with control, which was arbitrarily set at 1.0. Data shown are the mean 6 SD of three experiments (*P < 0.001). B: Dose-dependent
inhibition of AGA-induced TNF-a release in retinal microglial cells by inhibitor for ERK (U0126). Cells were treated with 500 mg/mL of AGA for 4 h
in the presence of indicated concentrations of inhibitor. TNF-a levels were compared with the vehicle-treated control. Data shown are the mean 6
SD of three to ﬁve experiments. C: U0126 also had no effect on cell viability, as determined by trypan blue exclusion test. D: Inhibition of
A.S. IBRAHIM AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, APRIL 2011 1127AGA induces TNF-a release by retinal microglial cells
in vitro. After having shown that AGA plays a role in
diabetes-induced retinal inﬂammation, we next sought to
dissect out the mechanism(s) responsible for the observed
effect. Therefore, a cultured retinal microglia model was
developed to characterize the microglial response to AGA
treatment. The purity of this culture preparation was assessed
by immunocytochemistry and ﬂow cytometry. By immuno-
cytochemistry, the majority was Iba1-positive, whereas the
contaminating astrocytes were insigniﬁcant. By ﬂow cytom-
etry, the purity of microglia was 96.6% (Fig. 3A)a n dG F A P -
positive cells were less than 1% (data not shown). With the
use of this model, incubation with AGA (500 mg/mL) sig-
niﬁcantly stimulated TNF-a production starting at 4 h and
remained elevated over the 24-h experimental period,
whereas incubation with nonglycated albumin for 1–24 h
had no effect (Fig. 3B). Moreover, there was nonsigniﬁcant
cell death after 4 h of AGA treatment (Supplementary
Fig. 3). To verify that the stimulatory effect of AGA on
TNF-a release was mediated by glycated albumin only and
not by endotoxin or any other contaminants, we ﬁrst
checked the endotoxin level in AGA solutions used in this
study and conﬁrmed to be endotoxin free (,0.125 units/mL,
10 endotoxin unit = 1 ng lipopolysaccharide). This estimated
contamination of endotoxin was clearly below the threshold
concentration of puriﬁed lipopolysaccharide (LPS) (0.1–10
ng/mL) required for a signiﬁcant microglial stimulation
(Fig. 3C). Moreover, to fully exclude the possible effects that
any contaminating traces of endotoxin AGA still might have
on the observed inﬂammatory response, we preincubated
AGA-containing media with LPS-binding polymyxin B. At
a concentration of 1 mg/mL, polymyxin B resulted in 90%
inhibition of TNF-a production in microglia activated by
puriﬁed LPS (1 mg/mL) without affecting cell viability (90–
93% compared with 90–95% for controls). The incubation of
AGA (500 mg/mL) with the same concentration of polymyxin
B did not reduce the TNF-a production induced by AGA,
whereas the overall TNF-a production was clearly smaller
in AGA-incubated cells than that induced by puriﬁed LPS
(Fig. 3D). Thus, the stimulatory effect of the AGA on TNF-a
release from microglia is independent of contamination with
endotoxin.
Second, to ensure that the AGA-mediated TNF-a release
was indeed due to glycated albumin only and not to any
contaminant that might be associated with the commercially
available preparation, we compared the TNF-a–releasing
ability of the puriﬁed AGA with that of the unpuriﬁed one.
Puriﬁcation of AGA, which resulted in a preparation with
70–75% yield, had a TNF-a–releasing activity 34 6 3% higher
than the unpuriﬁed one (Fig. 3E). Following this further, we
tested the ability of an alternative AGA preparation,
obtained from Exocell Inc., to elicit the inﬂammatory re-
sponse in microglia. As shown in Fig. 3F, a signiﬁcant in-
crease in TNF-a level was seen after 4 h of incubation with
this alternative product compared with nonglycated albu-
min. The amount of TNF-a released from microglia in re-
sponse to glycated albumin varied with the degree of
protein glycation as seen in these two alternative prepa-
rations. Last, to further conﬁrm the speciﬁc effect of AGA
on TNF-a production, the AGA-neutralizing antibody,
A717, was used. The increase in TNF-a level mediated by
AGA was reduced signiﬁcantly by preincubation with
A717, but not with IgG (Fig. 3G). Collectively, these results
indicate that AGA induces TNF-a release by retinal
microglial cells in vitro and that increase is indeed con-
secutive to a glycated albumin effect and not to species
difference, endotoxin, or any other minor contaminants.
AGA-induced TNF-a release in retinal microglia is
mediated by MAPKs. In light of AGA’si n ﬂammatory
ability to induce TNF-a release by microglia, interest in the
molecular mechanisms underlying this response has been
expanded to include ERK, P38, and JNK MAPK pathways.
Whether or not these kinases are involved in AGA-induced
TNF-a release was investigated. Sustained elevation of
ERK phosphorylation occurred over the 8-h experimental
period (Fig. 4A), and that pattern is particularly indicative
of its role in microglial response to AGA exposure. To
determine the causal role of ERK in mediating TNF-a re-
lease, two approaches were used. First, an ERK inhibitor,
U0126, signiﬁcantly inhibited AGA-induced TNF-a release
in a dose-dependent manner, without affecting cell viabil-
ity (Fig. 4B and C). Second, microglia were transiently
transfected with ERK siRNA or with scrambled siRNA and
treated with AGA as before. ERK, but not scrambled siRNA,
signiﬁcantly inhibited TNF-a release (Fig. 4D, a and b).
Concomitant with ERK activation, phosphorylation of P38
occurred transiently at 1–4 h after AGA treatment (Fig. 4E).
Because P38 has complicated species multiplicity, we used
SB203580, a compound that inhibits P38 family of MAPK but
not other MAP kinases (26), to study the causal role of p38
in mediating TNF-a release. SB203580 signiﬁcantly inhibited
TNF-a release without affecting cell viability (Fig. 4F and G).
To conﬁrm these results, another selective p38 inhibitor,
SB202190, was also used. As did SB203580, SB202190 sig-
niﬁcantly reduced TNF-a production in a dose-dependent
manner without affecting cell viability (Supplementary
Fig. 4A–C). In contrast, phosphorylation of JNK remained
unchanged over the entire experimental period (Fig. 4H),
and its inhibitor (SP610025) did not inhibit AGA-induced
TNF-a release (Fig. 4I). These results demonstrate that ac-
tivation of ERK and P38, but not JNK, mediates AGA-induced
TNF-a release in retinal microglia.
Crosstalk between ERK and P38 pathways in AGA-
treated microglia. Next, we further determined any in-
teraction between ERK and P38 pathways in the AGA-treated
retinal microglia by examining the effect of P38 and ERK
inhibitors on self and mutual activation. U0126, which blocks
MEK, upstream of ERK, blocked the phosphorylation of both
AGA-induced TNF-a release by ERK siRNA in retinal microglial cells. Cells were transfected with siRNA or scrambled siRNA for 48 h and then
treated with AGA for 4 h. a, Measurement of ERK expression relative to actin by Western blot after transfection with anti-ERK siRNA. Data shown
are the mean 6 SD of three experiments. b, ELISA-measured TNF-a levels were compared with the scrambled siRNA-transfected control. Data
shown are the mean 6 SD of three experiments. E and H: Time-dependent, AGA-induced activation of P38 and JNK in retinal microglial cells. Cells
were treated with 500 mg/mL AGA for 1–8 h. Phospho (p)P38, pJNK, and its total proteins in cell lysates were determined by Western analysis.
Ratios of the intensities of phospho-proteins relative to total proteins for each time points were compared with control, which was arbitrarily set at
1.0. Data shown are the mean 6 SD of three experiments (*P < 0.001). F and I: Dose-dependent inhibition of AGA-induced TNF-a release in retinal
microglial cells by inhibitors for P38 (SB203580) and JNK (SP610025). Cells were treated with 500 mg/mL of AGA for 4 h in the presence of
indicated concentrations of inhibitors. TNF-a levels were compared with the vehicle-treated control. Data shown are the mean 6 SD of three to ﬁve
experiments. G: Effect of SB203580 on cell viability, as determined by trypan blue exclusion test.
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phosphorylation of both P38 and ERK. Further, we deter-
mined whether ERK and P38 both contributed to TNF-a re-
lease. Microglia were pretreated with U0126 and SB203580
individually or in combination and then activated by AGA.
The combination of ERK and P38 inhibitors further inhibited
TNF-a release than either one did individually (Fig. 5B).
AGA-induced reactive oxygen species formation cau-
ses MAPKs activation and TNF-a release in microglia.
Despite these observations, the information regarding signal
transduction from the microglial AGA receptor to ERK/P38-
induced cytokine secretion remains largely unknown. Re-
active oxygen species (ROS) production has been shown to
be an early event induced in response to glycated protein
stimulus (27). To test whether ROS is causally related to
MAPKs-mediated TNF-a release, we ﬁrst tested the contri-
bution of ROS formation to AGA-induced TNF-a release. As
shown in Fig. 6A–C, the inhibitory effects of an antioxidant,
cannabidiol (CBD) (28), on ROS formation and TNF-a re-
lease without affecting cell viability demonstrate that ROS
formation is a causative event in AGA-induced TNF-a re-
lease from microglia. Next, to determine whether ROS
causally inﬂuenced MAPKs activation, phosphorylation of
ERK and P38 was measured in AGA-treated microglia in
the presence and absence of CBD. As shown in Fig. 6D
and E,C B Ds i g n i ﬁcantly attenuated the phosphorylation
of ERK and P38, indicating that oxidative stress is a com-
mon signaling event that is located upstream of both ERK/
P38 pathways mediating TNF-a release in AGA-treated
microglia.
DISCUSSION
Recent studies have shown that retinal inﬂammation is
a relatively early event that occurs in the context of DR
before vascular dysfunction (29–32). Microglial activation
has been recognized as a potential culprit mechanism
contributing to this early inﬂammatory outcome (3,24).
However, the mechanism by which diabetes activates
microglia to release inﬂammatory cytokines remains a
critical missing link. If such a link is established, clinical
interventions with agents that target these early features of
DR would provide long-term vascular beneﬁts. Hypergly-
cemia is still considered the principal cause of diabetes
complications, and its deleterious effects are attributed,
among other things, to the formation of the so-called AGA.
In this study, we put forward a new concept pertaining to
the involvement of AGA in the genesis of diabetes-induced
retinal microglial activation and inﬂammation.
Microglia are sensitive to small changes in their envi-
ronment, and they can be activated by a variety of factors,
including proinﬂammatory cytokines, lipopolysaccharide,
damaged cells, or any immune-stimulatory agents (33).
Activated microglia have phagocytic and cytotoxic abili-
ties to destroy foreign materials by secreting cytokines and
other signaling molecules. However, if microglia remain in
a sustained activated state, the secreted cytokines can affect
other cell types in the proximity, particularly neuronal and
vascular cells (34), bringing about the progression of many
retinal diseases, including retinal degeneration (35) and
glaucoma (36). Given these functions, microglial activation
represents an important player in the pathogenesis of DR.
This input has originated partly from histopathologic studies
that show clustering of apparently activated microglia in the
diabetic rat retina (37,38). These initial observations have
been supported in postmortem human retinas (39) and
reinforced by additional histopathologic studies showing
that many inﬂammatory molecules, such as TNF-a,c a nb e
detected in the diabetic retina, often in association with
microglia (24,40). The retinal expression of TNF-a has been
reported to be associated with neuronal and endothelial cell
FIG. 5. Positive crosstalk occurs between ERK and P38 in AGA-treated
retinal microglial cells. A: Effect of P38 and ERK inhibitors on AGA-
induced MAP kinase activation. Cells were treated with AGA in the
presence or absence of P38 inhibitor (SB203580) and ERK inhibitor
(U0126) for 4 h. Phospho-ERK, total ERK, phospho-P38, and total P38
MAPK were determined as above. Each AGA-treated sample with or
without inhibitors was compared with the untreated sample, set as 1.0.
Data shown are the mean 6 SD of three experiments. $P < 0.05; #P <
0.05; and **P < 0.001. B: Effect of individual vs. combined ERK and P38
inhibitors on TNF-a release. Cells were treated with U0126 or
SB203580 alone or in combination for 30 min. Cells were then treated
with AGA (500 mg/mL) for 4 h. TNF-a levels were compared with the
vehicle-treated control. Data shown are the mean 6 SD of three
experiments.
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hibition of TNF-a has demonstrated beneﬁcial effects in the
prevention of early DR (43). Moreover, the in vitro studies
on co-cultured retinal neurons R28 with activated microglia
have shown that microglia produce cytotoxins that kill
retinal neuronal cells (3).
All of this seemingly overwhelming evidence has sculpted
the concept of activated microglia as a contributing factor
FIG. 6. ROS formation is an early event involved in AGA-induced TNF-a release and MAPKs activation in retinal microglial cells. A: AGA-induced,
time-dependent ROS formation in retinal microglial cells. ROS formation was prevented by pretreatment with CBD (2 mmol/L). Retinal microglial
cells loaded with 29,79-dichlorodihydroﬂuorescein diacetate were pretreated with CBD or DMSO for 60 min and treated with AGA, and the ﬂuo-
rescence of DCF was measured at 0, 2, 15, or 30 min. ROS formation was expressed as changes in DCF ﬂuorescence/mg protein. Data shown are the
mean 6 SD of six experiments. B: Dose-dependent inhibition of AGA-induced TNF-a release in retinal microglial cells by CBD. Cells were treated
with 500 mg/mL of AGA for 4 h in the presence of indicated concentrations of CBD. TNF-a levels were compared with the vehicle-treated control.
C: Effect of CBD on cell viability, as determined by trypan blue exclusion test. Data shown are the mean 6 SD of three experiments. D and E: CBD
inhibits AGA-induced MAPKs activation in retinal microglial cells. Cells were treated with vehicle or CBD 30 min before AGA treatment for 4 h.
Phospho-ERK, total ERK, phospho-P38, and total P38 MAPK were determined by Western blot and quantiﬁed by densitometric analyses. Each
AGA-treated sample with or without inhibitors was compared with the untreated sample, set as 1.0. Data shown are the mean 6 SD of three
experiments. *P < 0.001.
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suming different morphologies and functions, reactive
macrogliosis, in response to changes in their environment.
In Mueller cells of the retina, de novo expression of GFAP is
indicative of any kind of impairment of the retina, including
experimental DR (44). This overexpression of Mueller
GFAP starts to be obvious at 8 weeks of diabetes (45).
Consistent with these previous studies, similar changes in
morphology and antigen-expression patterns of retinal glial
cells during diabetes were observed, such as hypertrophic
microglia with increased expression of their markers and
GFAP-positive Mueller cells. However, this study is the ﬁrst
to show that the acquisition of gliotic features within the
diabetic retina was characterized by the activation of ERK
and P38 exclusively in microglia but not in Mueller cells or
astrocytes.
We then sought to determine what causes microglial ac-
tivation and the accompanying increased inﬂammatory
cytokines in the diabetic retina. One hypothesis that has
been under investigation in other organs and has been
raised by our initial Western and microscopic studies is
AGA/inﬂammation cascade hypothesis. We have shown that
AGA is increased in rats with diabetes compared with rats
without diabetes and is localized in regions of microglial
distribution. These ﬁndings, together with the observations
that A717 signiﬁcantly attenuated the expression of both
Iba1 and TNF mRNA in 8-week diabetic rats and that
intravitreal injection of AGA per se in normal rats induced
Iba-1 expression and TNF-a release, have strengthened the
notion that increased levels of AGA in the diabetic retina
are an important contributor to microglial activation and
thereby inﬂammation. The accumulation of AGA within the
diabetic retina could be explained in part by the vascular
leakage (Fig. 2B) that occurs early during experimental
diabetes in the venules and capillaries of the superﬁcial
inner retinal vasculature (46). This vascular leakage pro-
motes microvascular permeability and thereby enhances
the direct contact of plasma-borne glycated albumin with
the inner retinal layer, modulating the production of cyto-
kines by microglia. However, the microvascular leakage is
not the only contributor to the increased retinal AGA, and
the possibility of local AGA formation cannot be ruled
out (17).
Accordingly, the direct relationship between microglia
and AGA has been explored through in vitro study. Wang
et al. (27) reported that glycated proteins may alter mi-
croglia function by enhancing intracellular ROS formation
and activating MAPKs-mediated TNF-a release but did not
portray the causal relationship among these pathways.
We expanded on that study and demonstrated two clear
ﬁndings: AGA triggers the secretion of TNF-a, which is
varied with the degree of protein glycation, and this in-
ﬂammatory response is mediated by ROS and its subsequent
signaling, ERK and P38 but not JNK MAPK. Furthermore,
we broadened the scope to include the crosstalk between
ERK and P38 pathways in microglia after AGA treatment.
Inhibition of ERK by U0126 led to decreased phosphoryla-
tion of P38 MAPK, whereas blocking P38 phosphorylation
by SB 203580 resulted in a reciprocal increase in the phos-
phorylation of ERK. In addition, even though SB 203580 is
an inhibitor of p38 activity, it was also seen to increase
p38 phosphorylation; although unexplained at this point, the
observation has been reported (47). Similar to retinal
microglia, concurrent activation of ERK and P38 occurs
in melanoma, and the positive crosstalk between ERK
and P38 in melanoma stimulates migration and in vivo
proliferation (48). This positive crosstalk is in direct contrast
with carcinoma cells in which the activity of the two kinases
seems to be mutually exclusive (49). However, our results
a r en o ti na g r e e m e n tw i t ht h es t u d yb yW a n ge ta l .s h o w i n g
that the production of TNF-a was mediated by ERK, P38,
and JNK (27). This discrepancy may be explained by the use
of a different JNK inhibitor, curcumin (50 mmol/L), which
shows a broad selectivity for various targets and is a potent
scavenger of free radicals (50). Together, these inhibitor
experiments point out that AGA-induced TNF-a is mediated
by two alternative pathways partially interacting with each
other. Figure 7 illustrates these pathways and the mecha-
nism by which various drugs block these processes. Al-
though these in vitro data provide a mechanistic paradigm
whereby AGA induces microglial inﬂammatory response,
used at nonphysiologic exposure condition (500 mg/mL), the
relevance of these ﬁndings at lower AGA exposure levels
needs to be further investigated.
Collectively, the experiments in this study provide new
insights in understanding the pathogenesis of early fea-
tures of DR, demonstrating that the accumulation of AGA
within the diabetic retina elicits the microglial activation
and secretion of TNF-a. In addition, our in vitro data dis-
close the molecular mechanisms involved therein, show-
ing that AGA triggers TNF-a release from microglia in
ROS and its subsequent ERK and P38 MAPKs-dependent
mechanisms. Thus, clinical intervention trials with agents
that neutralize glycated albumin effect might be war-
ranted in modulating early pathologic pathways long be-
fore the occurrence of vision loss among patients with
diabetes.
FIG. 7. Signaling pathways in the diabetes-induced retinal inﬂam-
mation. Diabetes-induced AGA leads to ROS formation, activation of
ERK/P38, and TNF-a release during microglial activation. Also in-
cluded is the mechanism by which various drugs block these pro-
cesses. (A high-quality color representation of this ﬁgure is available
in the online issue.)
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